Entremed reports patent issuance for its lead drug candidate ENMD-2076

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today announced the issuance by the Chinese State Intellectual Property Office of Patent Certificate No. ZL 200680044656.7.  The granted claims are directed to ENMD-2076, covering composition of matter and uses to treat various cancers.  The patent is part of EntreMed's broad intellectual property portfolio for ENMD-2076.

"We are very pleased with the issuance of this patent in China for ENMD-2076," said Ken K. Ren , Ph.D., the Company's Chief Executive Officer.  "This patent provides intellectual property protection for ENMD-2076 in a market that is experiencing tremendous growth and of which we intend to capitalize on.  The issuance of this patent broadens our existing international patent estate for ENMD-2076 and also confirms the Chinese State Intellectual Property Office's recognition that ENMD-2076 represents new and inventive chemical structures." 

ENMD-2076 has completed and shown activity in Phase 1 clinical trials in solid tumor cancers, leukemia, multiple myeloma, and is completing a Phase 2 trial for ovarian cancer.  A Phase 2 triple-negative breast cancer trial at the University of Colorado and Indiana University and a Phase 2 trial in advanced/soft tissue sarcoma at Princess Margaret Hospital are currently enrolling.  As part of its global development strategy utilizing China resources, EntreMed has submitted a new drug clinical trial application with the Chinese Food and Drug Administration (CFDA) for ENMD-2076 to conduct global clinical trials in triple-negative breast cancer patients.